UF startup Kriya Therapeutics, Inc., a clinical-stage biopharmaceutical company developing gene therapies to address common chronic diseases of high unmet need, announced the closing of a $320 million Series D financing. The round was co-led by Patient Square Capital and Premji Invest, with participation from other leading life sciences and technology-focused investors including Peter Thiel, Narya Capital, The T1D Fund: A Breakthrough T1D Venture, LLC and other long-term investors. The round was oversubscribed and completed at a significant step up to the previous round of financing. Akshay Rai from Premji Invest has joined Kriya’s Board of Directors in conjunction with this financing.
Read more about Kriya Announces $320 Million Series D Financing to Advance Pipeline of Gene Therapies for Chronic Diseases of High Unmet Need.
